SLP
Simulations Plus Inc
$
35.320
- Overview
- Forecast
- Valuation
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
36.040
Open
36.000
VWAP
35.50
Vol
59.34K
Mkt Cap
713.94M
Low
35.130
Amount
2.11M
EV/EBITDA(TTM)
59.83
Total Shares
19.98M
EV
692.56M
EV/OCF(TTM)
58.98
P/S(TTM)
9.17
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
21.84M
+15.43%
--
--
26.17M
+39.97%
--
--
22.92M
+23.58%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Simulations Plus, Inc. (SLP) for FY2025, with the revenue forecasts being adjusted by -0.04% over the past three months. During the same period, the stock price has changed by 3.91%.
Revenue Estimates for FY2025
Revise Downward
-0.04%
In Past 3 Month
Stock Price
Go Up
+3.91%
In Past 3 Month
6 Analyst Rating
35.19% Upside
Wall Street analysts forecast SLP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLP is 47.75 USD with a low forecast of 40.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
35.19% Upside
Current: 35.320
Low
40.00
Averages
47.75
High
65.00
35.19% Upside
Current: 35.320
Low
40.00
Averages
47.75
High
65.00
Keybanc
Scott Schoenhaus
Buy
Maintains
$32 → $40
2025-04-16
Reason
Keybanc
Scott Schoenhaus
Price Target
$32 → $40
2025-04-16
Maintains
Buy
Reason
KeyBanc raised the firm's price target on Simulations Plus to $40 from $32 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.
Keybanc
Brett Fishbin
Buy
Maintains
$35 → $37
2025-01-24
Reason
Keybanc
Brett Fishbin
Price Target
$35 → $37
2025-01-24
Maintains
Buy
Reason
KeyBanc raised the firm's price target on Simulations Plus to $37 from $35 and keeps an Overweight rating on the shares. The firm notes shares are trading at 6-times FY25 EV/Street revenues, which is toward the lower end of its digital biology peers' valuations, particularly since it expects high-teens revenue growth over the next several years, with adjusted EBITDA margins of 35%-plus. Also, Simulations Plus's next twelve months revenue multiple is well below its IPO levels of about 20-turns in early 2021 and well below its next twelve months adjusted EBITDA levels of 65-turns, KeyBanc adds.
Keybanc
Scott Schoenhaus
Buy
Maintains
$40 → $35
2025-01-08
Reason
Keybanc
Scott Schoenhaus
Price Target
$40 → $35
2025-01-08
Maintains
Buy
Reason
KeyBanc lowered the firm's price target on Simulations Plus to $35 from $40 and keeps an Overweight rating on the shares. The firm notes healthcare technology stocks were under pressure for most of last year but saw a rebound in the last two months following the Trump election. In combination with consensus estimate cuts since the middle of last year, KeyBanc sees attractive buying opportunities in the space in 2025. From a valuation multiple perspective, the firm believes companies with healthy balance sheets and steady free cash flow profiles will see less risk to multiple contraction, even with more modest growth trends. Conversely, it sees the most risk for companies that have challenged balance sheets and limited profitability in the near and longer term.
Stephens & Co.
Jeff Garro
Buy
Initiates
$39
2024-11-15
Reason
Stephens & Co.
Jeff Garro
Price Target
$39
2024-11-15
Initiates
Buy
Reason
Stephens analyst Jeff Garro initiated coverage of Simulations Plus with an Overweight rating and $39 price target. Simulations Plus addresses a core problem in life sciences clinical research, namely the high costs to develop drugs with low probability of success, and has a demonstrated ROI by using computer models predicting the interactions between the human body and drugs to accelerate clinical research, the analyst tells investors. The firm sees signs of the end market stabilizing, a favorable combination of recent sales execution and differentiated growth strategy, and a coming reversal in EBITDA margins leading to multiple expansion as "this thesis plays out," the analyst added.
William Blair
Max Smock
Buy
Reiterates
n/a
2024-11-06
Reason
William Blair
Max Smock
Price Target
n/a
2024-11-06
Reiterates
Buy
Reason
BTIG
David Larsen
Strong Buy
Maintains
$60 → $50
2024-10-24
Reason
BTIG
David Larsen
Price Target
$60 → $50
2024-10-24
Maintains
Strong Buy
Reason
BTIG lowered the firm's price target on Simulations Plus to $50 from $60 and keeps a Buy rating on the shares after its Q4 earnings beat and above-consensus guidance. The firm is positive on the company's expected improvement in margins as it works towards its long-term adjusted EBITDA margin goal of 35%-40%, though it also warns regarding the "ongoing macro headwinds and lumpy Software results" in cutting its price target, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Simulations Plus Inc (SLP.O) is 51.64, compared to its 5-year average forward P/E of 80.80. For a more detailed relative valuation and DCF analysis to assess Simulations Plus Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
80.80
Current PE
51.64
Overvalued PE
106.30
Undervalued PE
55.31
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
40.71
Current EV/EBITDA
21.32
Overvalued EV/EBITDA
58.74
Undervalued EV/EBITDA
22.68
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
15.69
Current PS
7.49
Overvalued PS
22.19
Undervalued PS
9.20
Financials
Annual
Quarterly
FY2025Q2
YoY :
+22.55%
22.43M
Total Revenue
FY2025Q2
YoY :
-38.95%
2.71M
Operating Profit
FY2025Q2
YoY :
-23.70%
3.07M
Net Income after Tax
FY2025Q2
YoY :
-25.00%
0.15
EPS - Diluted
FY2025Q2
YoY :
+10.47%
4.74M
Free Cash Flow
FY2025Q2
YoY :
-18.98%
58.52
Gross Profit Margin - %
FY2025Q2
YoY :
-46.98%
10.46
FCF Margin - %
FY2025Q2
YoY :
-37.76%
13.70
Net Margin - %
FY2025Q2
YoY :
-35.71%
3.96
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
1.2M
USD
2
3-6
Months
1.8M
USD
5
6-9
Months
1.4M
USD
4
0-12
Months
3.2M
USD
9
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 20615.77% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
199.7K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
964.0
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
2
1.8K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
1.2M
USD
2
3-6
Months
1.8M
USD
5
6-9
Months
1.4M
USD
4
0-12
Months
3.2M
USD
9
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SLP News & Events
Events Timeline
2025-04-03 (ET)
2025-04-03
16:07:38
Simulations Plus sees FY25 EPS $1.07-$1.20, consensus $1.09
2025-04-03
16:06:52
Simulations Plus reports Q2 EPS 31c, consensus 26c
2025-01-07 (ET)
2025-01-07
15:09:06
Simulations Plus backs FY25 adjusted EPS view $1.07-$1.20, consensus $1.09
Sign Up For More Events
Sign Up For More Events
News
4.5
04-11BenzingaGold Gains Over 2%; US Consumer Sentiment Dips In April
9.0
04-11BenzingaWhat's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
9.5
04-11BenzingaFastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
Sign Up For More News
People Also Watch
EBS
Emergent BioSolutions Inc
5.365
USD
-2.28%
HNRG
Hallador Energy Co
14.495
USD
-1.33%
QD
Qudian Inc
2.720
USD
+2.64%
OPAL
Opal Fuels Inc
1.750
USD
+0.57%
EBF
Ennis Inc
17.820
USD
-0.56%
CLFD
Clearfield Inc
29.155
USD
+0.05%
LASR
nLIGHT Inc
7.740
USD
-1.02%
TMCI
Treace Medical Concepts Inc
6.790
USD
+1.04%
TBLD
Thornburg Income Builder Opportunities Trust
17.860
USD
+0.28%
AMBC
Ambac Financial Group Inc
7.995
USD
+0.06%
FAQ
What is Simulations Plus Inc (SLP) stock price today?
The current price of SLP is 35.32 USD — it has decreased -0.51 % in the last trading day.
What is Simulations Plus Inc (SLP)'s business?
What is the price predicton of SLP Stock?
What is Simulations Plus Inc (SLP)'s revenue for the last quarter?
What is Simulations Plus Inc (SLP)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Simulations Plus Inc (SLP)'s fundamentals?
How many employees does Simulations Plus Inc (SLP). have?